NCT00182091View on ClinicalTrials.gov

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2010

Conditions
AcromegalyGrowth Hormone DeficiencyPituitary Disease
Interventions
DRUG

Recombinant human growth hormone

Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.

DRUG

Saline

To maintain study-subject blinding, doses were sham adjusted.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT00182091 - Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency | Biotech Hunter | Biotech Hunter